ArticleUlusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES2025
The effects of rose oil on liver damage in an experimental model of obstructive jaundice.
Article in Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigates the effects of Turkish rose oil (Rosa damascena) on liver damage in rats with experimentally induced obstructive jaundice.
methodsA total of 40 Wistar-Albino rats were divided into three groups: Sham (control), Obstructive Jaundice (OJ), and Rose Oil treatment (RO). Obstructive jaundice was induced by bile duct ligation in the OJ and RO groups. The RO group received 100 mg/kg of oral Turkish rose oil daily for seven days.
resultsBiochemical analysis showed significantly elevated levels of liver and biliary injury markers, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT), in the OJ group. These markers were significantly reduced in the RO group. Additionally, oxidative stress markers such as malondialdehyde (MDA) and myeloperoxidase (MPO) were lower in the RO group compared to the OJ group. Although levels of antioxidant enzymes, including glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD), were higher in the RO group, the differences were not statistically significant. Interestingly, C-reactive protein (CRP) levels were unexpectedly higher in the RO group than in the OJ group, possibly due to the study duration or dosing protocol. Histopathological examination revealed significant portal inflammation, bile duct proliferation, polymorphonuclear leukocyte (PMNL) infiltration, necrosis, and fibrosis in the OJ group. Conversely, the RO group showed substantial reductions in these pathological features, including milder bile duct proliferation and necrosis (p<0.001). Additionally, connective tissue expansion and collagen deposition were significantly lower in the RO group compared to the OJ group.
conclusionThe anti-inflammatory and hepatoprotective effects of Turkish rose oil, previously reported in the literature, were demonstrated in this study for the first time through oral administration. The findings highlight its potential in mitigating acute liver damage caused by obstructive jaundice. However, some unexpected biochemical results (e.g., elevated CRP and MDA levels) may be attributed to the short study duration, limited sample size, and lack of dose variation. Overall, Turkish rose oil emerges as a promising natural agent with significant hepatoprotective and anti-inflammatory properties. These results suggest that it may serve as a potential therapeutic option for liver damage associated with obstructive jaundice. Further studies are warranted to investigate varying dosages, longer treatment durations, and larger sample sizes to better understand its therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.